Literature DB >> 33771086

Patients with inflammatory bowel disease on immunosuppressive drugs: perspectives' on COVID-19 and health care service during the pandemic.

Kristian Marling Moum1, Bjørn Moum2,3, Randi Opheim2,4.   

Abstract

BACKGROUND AND AIMS: Patients with inflammatory bowel diseases (IBD) have experienced changes to the routine management because of the SARS-CoV-2 pandemic. The aim of this study was to examine patients with IBD's adherence to the restrictions imposed by society and the hospital, worries and concerns regarding medical treatment and clinical follow-up under the pandemic.
METHODS: IBD patients (≥18 years) at the outpatient clinic at Oslo University Hospital were included and answered a self-report questionnaire including concerns regarding their disease, medical therapy and follow-up during SARS-CoV-2 pandemic.
RESULTS: In total, 522 IBD patients were included, 317 Crohn's disease, 205 ulcerative colitis, 386 patients <50 years. Eighteen percent were in obligatory quarantine, and more often patients <50 years compared to patients ≥50 years. Five patients tested positive to SARS- CoV-2. A higher proportion <50 years reported worries for their medical treatment and risk of COVID -19 disease compared to those ≥50 years. Forty percent avoided family, two-thirds avoided friends, and 4% cancelled their scheduled consultation at the hospital. The hospital changed physical consultation to telephone consultation for 15% of the patients. The preferred follow-up was physical consultation. A higher proportion of the patients <50 years preferred telephone consultation compared to those ≥50 years. Four out of five IBD patients were satisfied with the information about their IBD and COVID-19.
CONCLUSIONS: SARS-CoV-2 pandemic affects the daily lives for patients with IBD. It is important to develop evidence-base guidelines in follow-up and treatment, as well as patient information about COVID-19and IBD.

Entities:  

Keywords:  COVID-19; Inflammatory bowel disease; SARS-CoV-2; health-care service; immunosuppressive drugs

Year:  2021        PMID: 33771086     DOI: 10.1080/00365521.2021.1901308

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  3 in total

1.  A Patient-Prioritized Agenda for Information Needs During the COVID-19 Pandemic: A Qualitative Study of Patients With Inflammatory Bowel Disease.

Authors:  Millie D Long; Mary E Grewe; Emily Cerciello; Laura Weisbein; Kyra Catabay; Michael D Kappelman
Journal:  Crohns Colitis 360       Date:  2021-09-19

2.  Impact of COVID-19 in Pediatric Patients and Young Adults with Inflammatory Bowel Disease.

Authors:  Tiago Magalhães; Maria Cristina Granado; Ana Rute Manuel; Maria do Céu Espinheira; Eunice Trindade
Journal:  GE Port J Gastroenterol       Date:  2022-03-09

3.  The impact of restrictions on psychological outcomes in patients with inflammatory bowel disease on biological treatment during the coronavirus pandemic in Norway.

Authors:  Randi Opheim; Kristian Marling Moum; Milada Cvancarova Småstuen; Bjørn Moum
Journal:  Qual Life Res       Date:  2022-09-20       Impact factor: 3.440

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.